Shares of Pliant Therapeutics Inc.
PLRX,
soared about 75% in premarket trading on Monday, the day after the company said a high dose of its experimental treatment for idiopathic pulmonary fibrosis met the primary and secondary endpoints in a Phase 2a clinical trial. Pliant, which is testing four different doses of bexotegrast, said 21 patients received the 320 milligram dose — the highest dose — and will continue to receive treatment for 24 weeks. The final data from the study is expected to come in the second quarter. Pliant’s stock has soared 109.8% over the past year, while the broader S&P 500
SPX,
is down 9.7%.
